Novel Diuretic Strategies for the Treatment of Heart Failure in Japan

DOI Web Site Web Site PubMed 被引用文献7件 参考文献63件
  • Dohi Kaoru
    Department of Cardiology and Nephrology, Mie University Graduate School of Medicine
  • Ito Masaaki
    Department of Cardiology and Nephrology, Mie University Graduate School of Medicine

この論文をさがす

抄録

Fluid management is of paramount importance in the treatment strategy of heart failure (HF), but the therapeutic efficacy of loop diuretic-based treatment for HF patients is limited by insufficient response and adverse effects. Clinical data establishing the efficacy and safety of tolvaptan, a selective oral vasopressin V2 receptor antagonist that induces aquaresis, have recently been accumulated over 3 years of daily clinical experience in Japan. Intravenous infusion of carperitide, a synthetic α-human atrial natriuretic peptide, has also been widely used as acute-phase therapy for acute decompensated HF in Japan. Combination therapy using loop diuretics, tolvaptan, and carperitide with differing and complementary mechanisms of action may maximize therapeutic activity, to minimize the dosage of loop diuretics and thereby reduce the adverse effects not only for volume removal but also for the stability of cardiorenal hemodynamics. (Circ J 2014; 78: 1816–1823)

収録刊行物

  • Circulation Journal

    Circulation Journal 78 (8), 1816-1823, 2014

    一般社団法人 日本循環器学会

被引用文献 (7)*注記

もっと見る

参考文献 (63)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ